Travaux scientifiques

Prof. Dr. Yeşim Eralp

193 publications. La source de l’information est indiquée à côté de chaque publication.

Retour au profil

  1. The predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2 alpha expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.10539 Source : ORCID

  2. Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy

    Oncology, 2011

    DOI 10.1159/000330766 PMID 21912195 13 citations (Europe PMC) Source : ORCID

  3. Glutathione S-transferase P1 polymorphisms are associated with time to tumor progression in small cell lung cancer patients

    Journal of B.U.ON., 2011

    Source : ORCID

  4. Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non-Small-Cell Lung Cancer: A Phase II Study

    Clinical Lung Cancer, 2011

    DOI 10.1016/j.cllc.2011.03.030 PMID 21729649 6 citations (Europe PMC) Source : ORCID

  5. Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.629 5 citations (OpenAlex) Texte intégral en libre accèsSource : ORCID

  6. Phase II study of lapatinib in combination with vinorelbine in patients with ErbB2-amplified recurrent or metastatic breast cancer

    Journal of Clinical Oncology, 2011

    DOI 10.1200/jco.2011.29.15_suppl.e13079 1 citation (OpenAlex) Source : ORCID

  7. Association between glutathione s-transferase P1 polymorphisms and time to tumor progression in small cell lung cancer patients.

    Journal of Clinical Oncology, 2010

    DOI 10.1200/jco.2010.28.15_suppl.e12041 1 citation (OpenAlex) Source : OpenAlex

  8. Phase II study of loading-dose ibandronate treatment in patients with breast cancer and bone metastases suffering from moderate to severe pain.

    Journal of Clinical Oncology, 2010

    DOI 10.1200/jco.2010.28.15_suppl.e19507 1 citation (OpenAlex) Source : ORCID

  9. Primary tubal cancers: a clinicopathological study of twenty cases

    Turkish Journal of Pathology, 2009

    DOI 10.5146/tjpath.2009.00978 Source : OpenAlex

  10. Immunohistochemically Defined T1N0 Breast Cancer Subgroups Have Different Clinical Outcomes. A Retrospective Turkish Oncology Group Study.

    Cancer Research, 2009

    DOI 10.1158/0008-5472.sabcs-09-3167 Texte intégral en libre accèsSource : OpenAlex

  11. Yolk sac tumours of the ovary: Evaluation of clinicopathological features and prognostic factors

    European Journal of Obstetrics & Gynecology and Reproductive Biology, 2009

    DOI 10.1016/j.ejogrb.2009.02.052 PMID 19419810 27 citations (Europe PMC) Source : OpenAlex

  12. Malignant Ovarian Germ Cell Tumors

    American Journal of Clinical Oncology, 2009

    DOI 10.1097/coc.0b013e3181841f2e PMID 19307952 17 citations (Europe PMC) Source : OpenAlex

  13. The outcome of patients with triple negative breast cancer: Evidence for a favorable ethnic subgroup? The Turkish Oncology Group experience

    Journal of Clinical Oncology, 2009

    DOI 10.1200/jco.2009.27.15_suppl.e22158 Source : ORCID

  14. BORDERLINE RESECTIONS AFTER NEO-ADJUVANT TREATMENT: SLEEVE LOBECTOMY VS. PNEUMONECTOMY

    Lung Cancer, 2009

    DOI 10.1016/s0169-5002(09)70246-6 Source : ORCID

  15. Clinical features associated with a favorable outcome following neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger

    Journal of Cancer Research and Clinical Oncology, 2009

    DOI 10.1007/s00432-008-0428-9 PMID 18581139 15 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  16. Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer

    Tumori Journal, 2009

    DOI 10.1177/030089160909500212 PMID 19579867 6 citations (Europe PMC) Source : ORCID

  17. Is the sentinel lymph node biopsy accurate for patients with initially clinically axilla-positive locally advanced breast cancer after neoadjuvant chemotherapy?

    Cancer Research, 2009

    DOI 10.1158/0008-5472.sabcs-5123 Source : ORCID

  18. Primary Tubal Cancers: A Clinicopathological Study of Twenty Cases

    Turk Patoloji Dergisi, 2009

    DOI 10.5146/tjpath.2009.01160 Source : ORCID

  19. TRASTUZUMAB BEYOND PROGRESSION IN PATIENTS WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER

    Journal of Breast Health, 2009

    Source : ORCID

  20. Lower Level of MAPK Expression Is Associated with Anthracycline Resistance and Decreased Survival in Patients with Hormone Receptor Negative Breast Cancer

    Cancer Investigation, 2008

    DOI 10.1080/07357900801891628 PMID 18608215 13 citations (Europe PMC) Source : OpenAlex

  21. Ovarian Carcinoma with Simultaneous Breast and Rectum Metastases

    Onkologie, 2008

    DOI 10.1159/000119121 PMID 18418023 6 citations (Europe PMC) Source : OpenAlex

  22. Bevacizumab – der neue Standard in der Darmkrebstherapie

    Onkologie, 2008

    DOI 10.1159/000127373 Texte intégral en libre accèsSource : OpenAlex

  23. Meetings and Conferences · Tagungen und Kongresse

    Onkologie, 2008

    DOI 10.1159/000127357 Texte intégral en libre accèsSource : OpenAlex

  24. PharmaNews

    Onkologie, 2008

    DOI 10.1159/000127375 Texte intégral en libre accèsSource : OpenAlex

  25. Factors affecting the prognosis of breast cancer patients with brain metastases

    The Breast, 2008

    DOI 10.1016/j.breast.2008.03.004 PMID 18455400 8 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  26. Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis

    Journal of Neuro-Oncology, 2008

    DOI 10.1007/s11060-008-9769-0 PMID 19099196 14 citations (Europe PMC) Source : OpenAlex

  27. Impact of adjuvant chemotherapy with respect to level of hormone receptor expression in patients with hormone responsive breast cancer: Implications for endocrine resistance

    Journal of Clinical Oncology, 2008

    DOI 10.1200/jco.2008.26.15_suppl.11563 Source : ORCID

  28. .ROLE OF VARIOUS METHODS OF BRACHYTHERAPY IN CARCINOMA OF VAGINA

    Radiotherapy and Oncology, 2008

    Source : ORCID

  29. Effect of adjuvant chemotherapy on integrity of free serum DNA in patients with breast cancer

    Annals of the New York Academy of Sciences, 2008

    DOI 10.1196/annals.1448.010 PMID 18837944 22 citations (Europe PMC) Source : ORCID

  30. Leptomeningeal dissemination of ovarian carcinoma through a ventriculopenitoneal shunt

    Gynecologic Oncology, 2008

    DOI 10.1016/j.ygyno.2007.09.024 PMID 17961641 20 citations (Europe PMC) Source : ORCID

  31. Predictive factors for local recurrence after breast conservative surgery following neoadjuvant chemotherapy: Our long-term results,Neoadjuvan kemoterapi sonrasi meme koruyucu cerrahide lokal nüksü etkileyen faktörler: Uzun dönem sonuçlarimiz

    Turk Onkoloji Dergisi, 2008

    Source : ORCID

  32. Predictive factors for local recurrence after breast conservative surgery following neoadjuvant chemotherapy: our long-term results

    Turk Onkoloji Dergisi, 2008

    Source : ORCID

  33. Size distribution of circulating cell-free DNA in sera of breast cancer patients in the course of adjuvant chemotherapy

    Clinical Chemistry and Laboratory Medicine, 2008

    DOI 10.1515/cclm.2008.080 PMID 18254709 38 citations (Europe PMC) Source : ORCID

  34. Neoadjuvan kemoterapi sonrası meme koruyucu cerrahide lokal nüksü etkileyen faktörler: Uzun dönem sonuçlarımız

    Istanbul Science University (Istanbul Bilim University), 2008

    Texte intégral en libre accèsSource : OpenAlex

  35. MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer

    Annals of Oncology, 2007

    DOI 10.1093/annonc/mdm522 PMID 18006896 51 citations (Europe PMC) Texte intégral en libre accèsSource : OpenAlex

  36. Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum

    Gynecologic Oncology, 2007

    DOI 10.1016/j.ygyno.2007.09.003 PMID 17936342 37 citations (Europe PMC) Source : OpenAlex

  37. MAPK expression is associated with poor outcome in patients with hormone receptor negative breast cancer

    Breast Cancer Research and Treatment, 2007

    Source : ORCID

  38. Multifocal breast cancer in women

    Cancer, 2007

    DOI 10.1002/cncr.22928 PMID 17676585 24 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  39. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer

    Medical Oncology, 2007

    DOI 10.1007/bf02685901 PMID 17673810 21 citations (Europe PMC) Source : ORCID

  40. Factors related with recurrence after complete pathologic response to post- operative chemotherapy in patients with epithelial ovarian cancer

    Annals of Oncology, 2006

    Source : ORCID

  41. Induction chemotherapy followed by chemoradiotherapy in patients with stage IIIA-B non-small cell lung cancer (NSCLC)

    Annals of Oncology, 2006

    Source : ORCID

  42. Serum levels of leptin and proinflammatory cytokinesin advanced stage non-small cell lung cancer

    Journal of Clinical Oncology, 2005

    DOI 10.1200/jco.2005.23.16_suppl.2594 1 citation (OpenAlex) Source : ORCID

  43. Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer

    Medical Oncology, 2005

    DOI 10.1385/mo:22:4:367 PMID 16260854 1 citation (Europe PMC) Source : ORCID

  44. The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients

    Acta Oncologica, 2005

    DOI 10.1080/02841860510007549 PMID 15788296 44 citations (Europe PMC) Texte intégral en libre accèsSource : ORCID

  45. Thymidine Labeling index: Prognostic role in breast cancer (vol 27, pg 400, 2004)

    American Journal of Clinical Oncology, 2005

    Source : ORCID

  46. Thymidine Labeling Index: Prognostic Role in Breast Cancer

    American Journal of Clinical Oncology, 2004

    DOI 10.1097/01.coc.0000128867.95368.9e PMID 15289735 2 citations (Europe PMC) Source : ORCID

  47. Body mass index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger

    Journal of Clinical Oncology, 2004

    DOI 10.1200/jco.2004.22.14_suppl.600 1 citation (OpenAlex) Source : ORCID

  48. Body mass index (BMI) is a predictor for response to neoadjuvant chemotherapy in women with localized breast cancer aged 35 years or younger

    Journal of Clinical Oncology, 2004

    DOI 10.1200/jco.2004.22.90140.600 Source : ORCID

  49. Induction chemotherapy with carboplatin and weekly paclitaxel followed by concomitant chemoradiation in locally advanced non-small cell lung cancer

    Journal of Clinical Oncology, 2004

    DOI 10.1200/jco.2004.22.90140.7270 Source : ORCID

  50. Induction chemotherapy with carboplatin and weekly paclitaxel followed by concomitant chemoradiation in locally advanced non-small cell lung cancer

    Journal of Clinical Oncology, 2004

    DOI 10.1200/jco.2004.22.14_suppl.7270 Source : ORCID